X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ASTRAZENECA PHARMA with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs MYLAN (US) - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   MYLAN
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
MYLAN
Dec-14
ASTRAZENECA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,2853,862-   
Low Rs6342,722-   
Sales per share (Unadj.) Rs189.61,322.1-  
Earnings per share (Unadj.) Rs-0.2159.3-  
Cash flow per share (Unadj.) Rs3.8256.4-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.6657.2-  
Shares outstanding (eoy) m25.00378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x5.12.5 203.3%   
Avg P/E ratio x-4,712.720.7 -22,801.8%  
P/CF ratio (eoy) x249.612.8 1,943.8%  
Price / Book Value ratio x14.05.0 279.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9881,245,533 1.9%   
No. of employees `0001.625.0 6.2%   
Total wages/salary Rs m1,6050-   
Avg. sales/employee Rs Th3,040.220,010.2 15.2%   
Avg. wages/employee Rs Th1,029.20-   
Avg. net profit/employee Rs Th-3.32,410.6 -0.1%   
INCOME DATA
Net Sales Rs m4,740500,256 0.9%  
Other income Rs m92-2,916 -3.2%   
Total revenues Rs m4,832497,340 1.0%   
Gross profit Rs m-130124,416 -0.1%  
Depreciation Rs m10136,742 0.3%   
Interest Rs m021,578 0.0%   
Profit before tax Rs m-13963,180 -0.2%   
Minority Interest Rs m0-259 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m52,657 0.2%   
Profit after tax Rs m-560,264 -0.0%  
Gross profit margin %-2.724.9 -11.0%  
Effective tax rate %-3.74.2 -87.1%   
Net profit margin %-0.112.0 -0.9%  
BALANCE SHEET DATA
Current assets Rs m2,726439,791 0.6%   
Current liabilities Rs m2,435343,829 0.7%   
Net working cap to sales %6.119.2 32.1%  
Current ratio x1.11.3 87.5%  
Inventory Days Days7478 94.5%  
Debtors Days Days41107 38.0%  
Net fixed assets Rs m1,035115,733 0.9%   
Share capital Rs m5017,690 0.3%   
"Free" reserves Rs m9420-   
Net worth Rs m1,716248,676 0.7%   
Long term debt Rs m0371,498 0.0%   
Total assets Rs m4,1561,001,646 0.4%  
Interest coverage xNM3.9-  
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x1.10.5 228.3%   
Return on assets %-0.18.2 -1.5%  
Return on equity %-0.324.2 -1.2%  
Return on capital %013.6 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Net fx Rs m-960-   
CASH FLOW
From Operations Rs m-865,759 -0.0%  
From Investments Rs m-146-51,859 0.3%  
From Financial Activity Rs m862-17,328 -5.0%  
Net Cashflow Rs m709-3,428 -20.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.8 Rs / USD

Compare ASTRAZENECA PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: ABBOTT INDIA  FDC LTD.  BIOCON LTD  IPCA LABS  PANACEA BIOTECH  



Today's Market

Global Markets Steady Despite North Korea Threat(RoundUp)

Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.

Related Views On News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 22, 2017 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS